Contributions
Abstract: 29
Type: Hot Topic
Abstract Category: N/A
Since 30 years Biologics are an innovative blessing for both, manufacturers and patients. In MS, Biologics represent the largest class of disease-modifying therapies by sales. However, their success is also associated with pressure on already tight healthcare budgets. Biosimilars, the replicas of innovative Biologics, offer the prospect of more affordable options and opens up opportunities for health systems to expand access to Biologics for more patients.
Since Biosimilars market entry over a decade ago, adoption of Biosimilars in the European Union has changed significantly. Initial concerns about the delivery mechanism, interchangeability and clinicians preferences were just some of the reasons for slow adoption of the first-generation products. In 2017 however, according to IQVIA MIDAS list-price data, Biosimilars doubled in size to € 3.5 bn globally and now represents 1.5% of total Biologics sales. It is Europe that continues to drive policy and uptake, with the European Economic Area contributing 69% growth to € 2.6 bn.
This presentation will provide an overview of the latest market developments and will highlight the drivers, challenges, and future opportunities of the European Biosimilar market.
Disclosure: nothing to disclose
Abstract: 29
Type: Hot Topic
Abstract Category: N/A
Since 30 years Biologics are an innovative blessing for both, manufacturers and patients. In MS, Biologics represent the largest class of disease-modifying therapies by sales. However, their success is also associated with pressure on already tight healthcare budgets. Biosimilars, the replicas of innovative Biologics, offer the prospect of more affordable options and opens up opportunities for health systems to expand access to Biologics for more patients.
Since Biosimilars market entry over a decade ago, adoption of Biosimilars in the European Union has changed significantly. Initial concerns about the delivery mechanism, interchangeability and clinicians preferences were just some of the reasons for slow adoption of the first-generation products. In 2017 however, according to IQVIA MIDAS list-price data, Biosimilars doubled in size to € 3.5 bn globally and now represents 1.5% of total Biologics sales. It is Europe that continues to drive policy and uptake, with the European Economic Area contributing 69% growth to € 2.6 bn.
This presentation will provide an overview of the latest market developments and will highlight the drivers, challenges, and future opportunities of the European Biosimilar market.
Disclosure: nothing to disclose